6,652 results on '"Latent Tuberculosis"'
Search Results
2. Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants (VPM1002)
3. COMPArison of Screening Strategies for Active TuBerculosis (COMPASS-TB) (COMPASS-TB)
4. Training Protocol on the Natural History of Tuberculosis
5. Immunization With BCG Vaccine to Prevent Tuberculosis Infection (TIPI)
6. Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection (PREVENT TB)
7. Clinic-based Versus Hotspot-focused Active TB Case Finding (CHASE-TB)
8. 2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB. (2R2)
9. Evaluation of ТВ/Flu-05Е Vaccine for the Prevention of Tuberculosis Infection in BCG-vaccinated Volunteers Aged 18-50 Years
10. Nurse-Led Community Health Worker Adherence Model in 3HP Delivery Among Homeless Adults at Risk for TB Infection and HIV (3HP-LTBI)
11. Effects of Tuberculosis Infection on Development and Function of the Placenta
12. PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia
13. High-parameter phenotypic characterization reveals a subset of human Th17 cells that preferentially produce IL-17 against M. tuberculosis antigen
14. Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial
15. Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis (SMA-TB)
16. Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV (DOLPHIN Moms)
17. Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively
18. Short-course Rifamycin-based Regimens for Latent Tuberculosis in Patients With End-stage Kidney Disease
19. One-month Latent Tuberculosis Treatment for Renal Transplant Candidates
20. Multicenter Italian Cohort Study on Tuberculosis in Pediatric Age
21. Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention
22. Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals
23. Improve Treatment Outcomes for Tuberculosis Infection in Tertiary Care Hospitals
24. Evaluating the Accuracy of New Tests for TB Infection Diagnosis (TB infection)
25. 1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam
26. Prevalence of Latent Tuberculosis Infection in Health-care Workers and Students (CROSSWORD)
27. Testing Health Workers At Risk to Advance Our Understanding of TB Infection (THWART-TB)
28. Brief Educational Video for Patients Prescribed LTBI Treatment
29. Short-course Regimens for the Treatment of Pulmonary Tuberculosis (CRUSH-TB)
30. Economic Incentives and vDOT for Latent Tuberculosis Infection
31. Clinical Practice Guidelines Versus Decision-support for Latent Tuberculosis Infection (LTBI) Management
32. 2023年重庆市高中学生结核分枝杆菌潜伏感染 现状及影响因素分析.
33. Usefulness of Xpert MTB/RIF and Xpert Ultra to Categorize Risk of Tuberculosis Transmission to Household Contacts.
34. Adherence to Short-Duration Treatment (3HP) for Latent Tuberculosis among International Migrants in Manaus, Amazonas: Evaluation of the Efficacy of Different Treatment Modalities.
35. Economic evaluation of diagnosis and treatment for latent tuberculosis infection among contacts of pulmonary tuberculosis patients in Thailand.
36. A retrospective analysis of transudative pleural effusion due to fibrosing mediastinitis.
37. Impact of in-utero exposure to HIV and latent TB on infant humoral responses.
38. Is yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings?
39. Preliminary X‐ray diffraction and ligand‐binding analyses of the N‐terminal domain of hypothetical protein Rv1421 from Mycobacterium tuberculosis H37Rv.
40. Expert views on screening for tuberculosis infection in patients commencing treatment with a biologic agent.
41. Latent Tuberculosis Screening Among New Users of a Biologic or Targeted Synthetic Disease‐Modifying Antirheumatic Drug: Gaps in Screening Overall and Among Janus Kinase Inhibitors.
42. Exosomal Small RNA Sequencing Profiles in Plasma from Subjects with Latent Mycobacterium tuberculosis Infection.
43. Predicting stringent QuantiFERON-TB Gold Plus conversions in contacts of tuberculosis patients
44. Risk of SDRs Under 3HP and 1HP Regimen for LTBI
45. BCG Revaccination in Children and Adolescents (BRiC)
46. Safety and Tolerability of Chlorquine in Addition to Anti-tuberculosis Therapy
47. Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention
48. TB Screening Improves Preventive Therapy Uptake (TB SCRIPT)
49. Comorbidities and Coinfections in Latent TB (COMBINE-TB)
50. Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.